James E. Fickenscher - Jan 23, 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
Chief Financial Officer
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Jan 23, 2023
Transactions value $
-$10,622
Form type
4
Date filed
1/25/2023, 04:28 PM
Previous filing
Jul 20, 2022
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Sale -$10.6K -17.8K -10.3% $0.60 155K Jan 23, 2023 Direct F1
transaction ZYNE Common Stock Award $0 +170K +109.86% $0.00 325K Jan 24, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F2 The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025.